| 1 |
Mariette C, Markar SR, Dabakuyo-Yonli TS, et al. Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer[J]. N Engl J Med, 2019, 380(2): 152-162.
|
| 2 |
Nuytens F, Dabakuyo-Yonli TS, Meunier B, et al. Five-Year Survival Outcomes of Hybrid Minimally Invasive Esophagectomy in Esophageal Cancer: Results of the MIRO Randomized Clinical Trial[J]. JAMA Surg, 2021, 156(4): 323-332.
|
| 3 |
Takeuchi H, Ando M, Tsubosa Y, et al. A randomized controlled phase Ⅲ trial comparing thoracoscopic esophagectomy and open esophagectomy for thoracic esophageal cancer: JCOG1409 (MONET trial)[J]. J Clin Oncol, 2024, 42(suppl 3): 249.
|
| 4 |
van der Wilk BJ, Eyck BM, Wijnhoven BPL, et al. Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial[J]. Lancet Oncol, 2025, 26(4): 425-436.
|
| 5 |
Printz C. Is active surveillance an alternative to surgery for some patients with esophageal cancer?[J]. CA Cancer J Clin, 2025, 75(4): 274-276.
|
| 6 |
Mukherjee S. Non-surgical approach to operable oesophageal cancer: is it prime time yet?[J]. Lancet Oncol, 2025, 26(4): 400-401.
|
| 7 |
Li Y, Zheng Y, Chen K, et al. The lost evidence: A phase III, multicenter randomized controlled trial of neoadjuvant chemotherapy paclitaxel plus cisplatin versus surgery alone for stage IIA–IIIB esophageal squamous cell carcinoma[J]. J Clin Oncol, 2025, 43(suppl 16): 4074.
|
| 8 |
Qin J, Xue L, Hao A, et al. Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial[J]. Nat Med, 2024, 30(9): 2549-2557.
|
| 9 |
Hoeppner J, Brunner T, Schmoor C, et al. Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer[J]. N Engl J Med, 2025, 392(4): 323-335.
|
| 10 |
Janjigian YY, Al-Batran SE, Wainberg ZA, et al. Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer[J]. N Engl J Med, 2025, 393(3): 217-230.
|
| 11 |
Shitara K, Rha SY, Wyrwicz LS, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study[J]. Lancet Oncol, 2024, 25(2): 212-224.
|
| 12 |
Kelly R, Ajani J, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): First results of overall survival (OS) from CheckMate 577[J]. J Clin Oncol, 2025, 43(suppl 16): 4000.
|